30 results about "Phosphorylethanolamine" patented technology

The invention discloses a mesenchymal stem cell serum-free culture medium. The culture medium takes an L-DMEM, DMEM-F12 or alpha-MEM culture medium as a basic culture medium and also includes the following addition components: fibronectin, laminin, transferrin, trypsin, aprotinin, growth hormone, insulin, hydrocortisone, dexamethasone, bFGF, EGF, B27, IGF-I, IGF-II, choline, linoleic acid, sodium selenite, phosphorylethanolamine, glutathione, vitamin C, vitamin E, vitamin B12 and biotin. The culture medium has the advantages of defined composition and controllable quality, and mesenchymal stem cells cultured by the culture medium grow normal; and after multiple passages, the 'dryness' of the mesenchymal stem cells and the ability of the mesenchymal stem cells to be differentiated into osteoblasts, chondrocytes, adipocytes, neurons and other types of cells are still kept.

The invention discloses a biomarker for an ossotide intervention therapy of osteoporosis. The biomarker comprises lipid and lipoid molecules, organic acid and derivatives thereof and/or neurotransmitter substances, wherein the lipid and lipoid molecules are any one or more selected from taurine, arachidonic acid, 1-palmitoyl-2-hydroxy-sn-3-phosphoethanolamine, (4Z, 7Z, 10Z, 13Z, 16Z, 19Z)-4, 7, 10, 13, 16, 19-docosahexaenoic acid, 1-stearoyl-2-hydroxy-sn-3-glycerol-3-phosphorylcholine, taurine deoxycholic acid, taurodeoxycholic acid and taurocholic acid. The invention discloses a screening method of the biomarker as well as an application of the biomarker. Exemplary research is provided for evaluation of active functions of natural products, and theoretical support is provided for systematic evaluation of anti-osteoporosis activity of ossotide and development of ossotide products with bioactive functions.

The invention discloses a limbus corneae stem cell serum-free medium and a culture method thereof. The serum-free medium comprises a basic culture medium and additives, wherein the additives include human recombinant EGF, insulin, 3,3',5-triiodo-L-thyronine, hydrocortisone, forskolin, manganese sulfate monohydrate, sodium selenite, sodium metasilicate, ammonium metavanadate, nickel chloride hexahydrate, stannous chloride dihydrate, ethanol amine, phosphorylethanolamine, ammonium molybdate tetrahydrate, 4-hydroxyethylpiperazine ethane sulfonic acid, vitamin C, bovine serum albumin, lipid concentrate and serum substitution. The serum-free medium contains no fetal calf serum or any animal source ingredient, can supply sufficient nutrients and good environment needed by cell growth proliferation and can effectively replace the effect of serum, cells grow well, the cell purity and stability are improved, rapid and stable cell sources are provided for limbus corneae stem cell specificity mechanism research and transplantation therapy, and the clinic application prospect is wide.

A method for the production of phosphoethanolamine is disclosed. Phosphoric acid and monoethanolamine are mixed at a sufficient ratio using a doser to form a solution. The solution is then esterified by heating the solution to about 200° C., followed by cooling the solution to 40° C. A sufficient amount of distilled water is added to the solution to produce the desired viscosity. Excess ethanol is then filtered from the solution via a suction element. The solution is then subjected to centrifugal action for up to four hours at 1800 RPM to separate the phosphoethanolamine until a moisture content below 20% is reached. The remainder is then air dried to further isolate the phosphoethanolamine.

A self-assembled discoidal PNA delivery vehicle includes a zwitterionic short chain diacyl lipid, a zwitterionic long chain diacyl lipid, a charged long chain diacyl lipid, a PEGylated lipid of the formula distearoyl phosphoethanolamine (DSPE)-PEG_n-TG, and an encapsulated PNA molecule with a defined molar ratio of the zwitterionic long chain diacyl lipid and the charged long chain diacyl lipid to the short chain diacyl lipid, the molar ratio of the charged long chain diacyl lipid to the zwitterionic long chain diacyl lipid, molar % of the PEGylated lipid to all lipids, and ratio of PNA to lipid. Also described are method of self-assembling the discoidal PNA delivery vehicle and methods of enhancing cellular uptake of PNA using the discoidal PNA delivery vehicle.

The invention provides a preparation method of 1, 2-dioleoyl-SN-glycerol-3-phosphorylethanolamine, which comprises the following specific steps: step S1, carrying out nucleophilic substitution reaction on (S)-glyceryl acetonide and diphenyl chlorophosphate under the action of first alkali to obtain [(R)-2, 2-dimethyl-1, 3-dioxolane-4-yl] diphenyl methyl phosphate, and carrying out condensation reaction on the [(R)-2, 2-dimethyl-1, 3-dioxolane-4-yl] diphenyl methyl phosphate under the action of second alkali to obtain [(R)-2, 2-dimethyl-1, 3-dioxolane-4-yl] diphenyl methyl phosphate; s2, carrying out a ring-opening reaction on the [(R)-2, 2-dimethyl-1, 3-dioxolane-4-yl] diphenyl methyl phosphate under the action of a first acid, so as to obtain (R)-2, 3-dihydroxypropyl diphenyl phosphate, and carrying out a ring-opening reaction on the [(R)-2, 2-dimethyl-1, 3-dioxolane-4-yl] diphenyl methyl phosphate under the action of a second acid, so as to obtain (R)-2, 3-dihydroxypropyl diphenyl phosphate; s3, the (R)-2, 3-dihydroxypropyl diphenyl phosphate and oleic acid are subjected to a condensation reaction under the action of a condensing agent, and 1, 2-dioleoyl-SN-glycerol-3-diphenyl phosphate is obtained; and step S4, enabling the 1, 2-dioleoyl-SN-glycerol-3-diphenyl phosphate to react with ethanolamine under the action of a second alkali, and then, carrying out hydrolysis under an acidic condition, so as to obtain the 1, 2-dioleoyl-SN-glycerol-3-phosphorylethanolamine.

Disclosed are compositions and methods for increasing the nutritional value of plants and plant parts. In illustrative embodiments PEAMT and ΔPEAMT polynucleotide and polypeptide compositions are disclosed as well as their use in modulating the levels of lipid compounds, and particularly, regulating the level of phosphatidylcholine, and its precursors in plants and seeds derived therefrom. Also disclosed are methods for modulating the level of glycine betaine and choline-O-sulfate in cells, and increasing the tolerance of transformed plants to osmotic and cryogenic stress.

The invention discloses a preparation method of L-alpha glyceryl phosphorylethanolamine (L-alpha-GPE), belonging to the technical field of development and application of lipid. The method comprises the following steps: using soya phospholipides powder as a raw material, in water phase, using phosphatidylethanolamine (PE) to produce L-alpha-GPE; respectively removing cations and anions by using the column chromatography of cation and anion exchange resin, purifying the column chromatography of silica gel, decoloring the active carbon, and conducting vacuum concentration to obtain the colorless and transparent L-alpha-GPE. By conducting HPLC-ELSD analysis, the chemical purity is 99.6%, the recovery rate is 66.5%, and by analysis through a polarimeter, the optical purity ee is 99%, and [alpha]<20>D=-3.26 degrees (H2Ocontent is 15.7%).

The present invention discloses rice fermentation substance and rice bran extract freeze-dried powder. The freeze-dried powder comprises the following components in percentage by mass: 4-5.5% of mannitol, 2.5-4% of trehalose, 1.5-2.5% of sodium hyaluronate, 0.03-0.07% of adenosine, 0.03-0.07% of xanthan gum, 1.5-2.5% of amino acid, 1.5-2.5% of pyrrolidone carboxylic acid, 1.5-2.5% of lactate, 1-1.5% of ceramide phosphorylethanolamine and 83-86% of water. The preparation method of the freeze-dried powder comprises the following steps of S1, weighing raw materials, stirring the raw materials ata constant speed, and performing heating to obtain a transparent solution I; S2, cooling the transparent solution I; S3, filtering the transparent solution I; S4, weighing the raw materials, adding the raw materials into the transparent solution I, stirring the raw materials at a constant speed, and performing heating to obtain a transparent solution II; S5, cooling the transparent solution II; S6, filtering the transparent solution II; S7, cleaning a penicillin bottle and performing drying sterilization; and S8, filling the penicillin bottle with the transparent solution II, and performing freeze-drying. The freeze-dried powder has the advantages that the effective components are high in stability and difficult to denaturize and inactivate, and the freeze-dried powder is convenient to carry and store.

An immunogenic glycan compound has a poly-beta-1,4-ManNAc repeating-unit structure variably modified with 6-linked phosphoethanolamine and 6-linked phosphoglycerol.